Altamira Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Altamira Therapeutics es Thomas Meyer , nombrado en Apr 2003, tiene una permanencia de 21.58 años. compensación anual total es $778.61K, compuesta por 55.9% salario y 44.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.59% de las acciones de la empresa, por valor de $8.75K. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 7.1 años, respectivamente.

Información clave

Thomas Meyer

Chief Executive Officer (CEO)

US$778.6k

Compensación total

Porcentaje del salario del CEO	55.9%
Permanencia del CEO	21.6yrs
Participación del CEO	0.6%
Permanencia media de la dirección	2.4yrs
Promedio de permanencia en la Junta Directiva	7.1yrs

Actualizaciones recientes de la dirección

Recent updates

Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID

Sep 13

Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio

Aug 30

Altamira starts development program for potential arthritis therapy

Jul 25

Altamira announces peer-reviewed publication on mRNA delivery platform

Jul 19

Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform

Jul 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thomas Meyer en comparación con los beneficios de Altamira Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$779k	US$435k	-US$9m
Jun 30 2023	n/a	n/a	-US$26m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$690k	US$396k	-US$20m
Sep 30 2022	n/a	n/a	-US$23m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$1m	US$401k	-US$7m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$741k	US$411k	-US$9m
Sep 30 2020	n/a	n/a	-US$8m
Jun 30 2020	n/a	n/a	-US$6m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$606k	US$376k	-US$7m
Sep 30 2019	n/a	n/a	-US$9m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	US$636k	US$370k	-US$12m
Sep 30 2018	n/a	n/a	-US$13m
Jun 30 2018	n/a	n/a	-US$16m
Mar 31 2018	n/a	n/a	-US$19m
Dec 31 2017	US$567k	US$373k	-US$25m

Compensación vs. Mercado: La compensación total ($USD778.61K) de Thomas está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD650.80K).

Compensación vs. Ingresos: La compensación de Thomas ha aumentado mientras la empresa no es rentable.

CEO

Thomas Meyer (56 yo)

21.6yrs

Permanencia

US$778,611

Compensación

Dr. Thomas Meyer, Ph.D. Founded Altamira Therapeutics Ltd. (formerly known as Auris Medical Holding Ltd.) (formerly known as Auris Medical Holding AG) in April 2003 and serves as Managing Director, Chairma...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Meyer	Founder	21.6yrs	US$778.61k	0.59% $ 8.8k
Marcel Gremaud	Chief Financial Officer	3yrs	sin datos	0.00094% $ 14.0
Covadonga Paneda	Chief Operating Officer	1.8yrs	sin datos	sin datos
Samuel Wickline	Chief Scientific Adviser	1.8yrs	sin datos	sin datos

2.4yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CYTO se considera experimentado (2.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Meyer	Founder	21.6yrs	US$778.61k	0.59% $ 8.8k
Alain Munoz	Independent Non-Executive Director	6.7yrs	US$59.34k	0.0082% $ 121.6
Mats Blom	Independent Non-Executive Director	7.6yrs	US$59.34k	0.0082% $ 122.0
Dominik Lysek	Director	less than a year	sin datos	sin datos

7.1yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de CYTO se considera experimentada (7.1 años de antigüedad promedio).

Altamira Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

High number of new directors

Altamira Therapeutics Ltd., Annual General Meeting, May 16, 2024

Altamira Therapeutics Ltd., Annual General Meeting, Jun 27, 2023

Altamira Therapeutics Ltd. Promotes Covadonga Pañeda to Chief Operating Officer, Effective January 1, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Altamira Therapeutics Receives Letter from Nasdaq Due to No Longer Complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules and Ineligibility for Any Cure Period

Altamira Therapeutics Ltd. to Report First Half, 2024 Results on Sep 24, 2024

Altamira Therapeutics Ltd. has completed a Follow-on Equity Offering in the amount of $3.989643 million.

Altamira Therapeutics Ltd. has completed a Follow-on Equity Offering in the amount of $3.989643 million.

Altamira Therapeutics Ltd. has filed a Follow-on Equity Offering.

Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 Mrna Delivered with Semaphore Nanoparticles in Animal Tumor Models

Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by Semaphore Nanoparticles

Altamira Therapeutics Ltd. Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management

High number of new directors

Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal

Altamira Therapeutics Ltd., Annual General Meeting, May 16, 2024

New minor risk - Financial data availability

Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal

Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

Altamira Therapeutics Ltd. has filed a Follow-on Equity Offering in the amount of $1.66 million.

Altamira Therapeutics Ltd. has filed a Follow-on Equity Offering in the amount of $1.66 million.

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Equity Requirement

An unknown private equity investor entered into a binding agreement to acquire 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd. (NasdaqCM:CYTO) for CHF 2.04 million.

An unknown private equity investor entered into a binding agreement to acquire 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd. (NasdaqCM:CYTO) for CHF 2.04 million.

New major risk - Share price stability

New minor risk - Share price stability

First half 2023 earnings released: CHF1.29 loss per share (vs CHF10.63 loss in 1H 2022)

Altamira Therapeutics Ltd. Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

Altamira Therapeutics Ltd., Annual General Meeting, Jun 27, 2023

Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

Altamira Therapeutics Provides Update on Clinical Trials with Bentrio

Altamira Therapeutics Ltd. Promotes Covadonga Pañeda to Chief Operating Officer, Effective January 1, 2023

Altamira Therapeutics Ltd. announced that it expects to receive $10 million in funding from Lincoln Park Capital, LLC

Less than half of directors are independent

Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement

An unknown buyer entered into an agreement to acquire Zilentin Ltd. from Altamira Therapeutics Ltd. (NasdaqCM:CYTO) for $2 million.

Less than half of directors are independent

Altamira Therapeutics Ltd. Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia

Altamira Therapeutics Re-Launches Bentrio in Europe for Allergic Rhinitis

Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19

Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID

Altamira Therapeutics Advances Talks to Divest Legacy Business

Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio

Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19

Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint

Altamira starts development program for potential arthritis therapy

Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy

Altamira announces peer-reviewed publication on mRNA delivery platform

Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform

Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis

Altamira Therapeutics Ltd. Announces Top-Line Data from AM-125 Phase 2 Study in Acute Vertigo

Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements

Founder recently bought US$54k worth of stock

High number of new and inexperienced directors

Altamira Therapeutics Ltd., Annual General Meeting, May 19, 2022

Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2

Auris Medical Holding Ltd. Announces the Publication of Positive Results from an in Vivo Study Demonstrating Significant Inhibition of Tumor Growth by siRNA Knock-down of NF-kB Employing Its OligoPhoretm

Auris Medical shares rise on OligoPhore Lymphoma study results

Auris Medical Holding Ltd. (NasdaqCM:EARS) acquired Trasir Therapeutics, Inc. for $2.8 million.

Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India

Auris Medical starts preparations for COVID-19 trial with Bentrio in India

Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU

Auris Medical Holding Ltd. Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo

Auris Medical updates on pollen challenge study for nasal spray

Auris Medical Holding Ltd. Provides Update on Bentrio Program in Allergy

New 90-day high: US$5.20

Auris Medical Holding Ltd. Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis

Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?

Auris Medical Holding Ltd. Reports Positive in Vitro Efficacy Data for Am-301 in Protecting Against Sars-Cov-2 Infection

Auris Medical prices $8M direct equity offering, stock -22%

New 90-day high: US$1.15

Auris Medical Holding Ltd. Announces Initiation of Part B of Travers Phase 2 Study with AM-125 in Vertigo